MedTrace Logo

Clinical Trials

NCT05279027 | ACTIVE_NOT_RECRUITING | EARLY_PHASE1
6 participants

Zr89 + PET Companion Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-03-08
Completion:
2026-07-31
Conditions
  • Melanoma (Skin)
Interventions
  • DRUG
No Results Yet
NCT05063552 | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3
430 participants

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2023-03-13
Completion:
2027-12-15
Conditions
  • Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Hypopharyngeal Squamous Cell Carcinoma
  • Metastatic Laryngeal Squamous Cell Carcinoma
  • Metastatic Lip and Oral Cavity Carcinoma
  • Metastatic Nasal Cavity Squamous Cell Carcinoma
  • Metastatic Nasopharyngeal Squamous Cell Carcinoma
  • Metastatic Pharyngeal Squamous Cell Carcinoma
  • Metastatic Sinonasal Squamous Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Squamous Cell Carcinoma
  • Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
  • Recurrent Nasopharyngeal Squamous Cell Carcinoma
  • Recurrent Pharyngeal Squamous Cell Carcinoma
  • Recurrent Sinonasal Squamous Cell Carcinoma
  • Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage IV Hypopharyngeal Carcinoma AJCC v8
  • Stage IV Laryngeal Cancer AJCC v8
  • Stage IV Lip and Oral Cavity Cancer AJCC v8
  • Stage IV Nasopharyngeal Carcinoma AJCC v8
  • Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IV Sinonasal Cancer AJCC v8
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • DRUG
No Results Yet
NCT05058651 | SUSPENDED | PHASE2/PHASE3
189 participants

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-06-28
Completion:
2028-10-01
Conditions
  • Advanced Extrapulmonary Neuroendocrine Carcinoma
  • Metastatic Extrapulmonary Neuroendocrine Carcinoma
  • Recurrent Extrapulmonary Neuroendocrine Carcinoma
  • Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • DRUG
  • OTHER
No Results Yet
NCT05045820 | ACTIVE_NOT_RECRUITING | NA
106 participants

Integrative Medicine in Pain Management in Sickle Cell Disease

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-06-29
Completion:
2025-06-20
Conditions
  • Sickle Cell Disease
  • Pain
  • Acupuncture
  • Quantitative Sensory Testing
  • Magnetic Resonance Imaging
  • Circulating Biomarkers
  • Electroencephalography
  • Functional Near-infrared Spectroscopy
Interventions
  • DEVICE
No Results Yet
NCT05019716 | RECRUITING | PHASE1/PHASE2
36 participants

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-07-13
Completion:
2027-06-07
Conditions
  • Advanced NUT Carcinoma
  • Metastatic NUT Carcinoma
  • Unresectable NUT Carcinoma
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
NCT04996875 | RECRUITING | PHASE2
140 participants

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-11-09
Completion:
2025-09-19
Conditions
  • Advanced Systemic Mastocytosis (AdvSM)
  • SM With an Associated Hematologic Neoplasm (SM-AHN)
  • Mast Cell Leukemia (MCL)
  • Aggressive Systemic Mastocytosis (ASM)
Interventions
  • DRUG
No Results Yet
NCT04981509 | RECRUITING | PHASE2
65 participants

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-06-10
Completion:
2027-12-31
Conditions
  • Hereditary Leiomyomatosis and Renal Cell Carcinoma
  • Papillary Renal Cell Carcinoma
  • Renal Cell Carcinoma
  • Sporadic Papillary Renal Cell Carcinoma
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • DRUG
No Results Yet
NCT04963153 | ACTIVE_NOT_RECRUITING | PHASE1
24 participants

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-07-07
Completion:
2026-12-01
Conditions
  • Locally Advanced Bladder Urothelial Carcinoma
  • Locally Advanced Renal Pelvis Urothelial Carcinoma
  • Locally Advanced Ureter Urothelial Carcinoma
  • Locally Advanced Urethral Urothelial Carcinoma
  • Locally Advanced Urothelial Carcinoma
  • Metastatic Bladder Urothelial Carcinoma
  • Metastatic Renal Pelvis Urothelial Carcinoma
  • Metastatic Ureter Urothelial Carcinoma
  • Metastatic Urethral Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Recurrent Bladder Urothelial Carcinoma
  • Recurrent Renal Pelvis Urothelial Carcinoma
  • Recurrent Ureter Urothelial Carcinoma
  • Recurrent Urethral Urothelial Carcinoma
  • Recurrent Urothelial Carcinoma
  • Stage IIIB Bladder Cancer AJCC v8
  • Stage IV Bladder Cancer AJCC v8
  • Stage IV Renal Pelvis Cancer AJCC v8
  • Stage IV Ureter Cancer AJCC v8
  • Stage IV Urethral Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page